The original program of the Chinese medical team successfully broke through the worldwide problem of leukemia bone marrow transplant donor deficiency, becoming the first choice for more than half of the world's haploid bone marrow transplant patients.
At the 7th Asian Cell Therapy Organization Annual Meeting, which was closed in Beijing on the 13th, experts from various countries confirmed the contribution of the program to the world.
As a malignant blood disease, leukemia mortality ranks first in children with malignant disease mortality and sixth in adult malignant disease mortality. The most effective way to treat the disease is to perform a hematopoietic stem cell transplant, or bone marrow transplant. However, bone marrow transplantation must be performed with 100% homogeneity of human leukocyte antigen (HLA), otherwise severe rejection will occur. But even the siblings, the probability of total coincidence is only 25%, and the population without blood relationship is only one in 100,000. Therefore, the lack of bone marrow donor sources has become a worldwide problem that has long plagued leukemia treatment.
Since the end of the last century, countries around the world have carried out clinical research on haploid bone marrow transplantation technology. The so-called haploid transplantation refers to a technique in which a patient can receive a transplant even when the bone marrow stem cells are half-matched. However, when this technology was first introduced, the patients who received the transplant had a large rejection response, and the survival rate after transplantation was only 20%.
Since 1996, the team led by Huang Xiaojun, director of the Institute of Hematology, Peking University, has begun to explore the mechanism of granulocyte colony-stimulating factor inhibiting cell rejection in humans. On this basis, Chinese original haploid bone marrow has gradually formed. Transplant technology system. Nowadays, this "habitat donor" haploid transplantation technology has matured, and its postoperative success rate is 70%, which is equivalent to the success rate of full-match bone marrow transplantation, while the success rate of similar transplantation technologies in Britain and the United States is only 40. %. As of the end of 2015, more than 5,000 Chinese leukemia patients have been cured through this program.
At present, the program is used in clinical practice in France, Italy, Israel, Japan, South Korea and other countries, covering more than 50% of the world's similar transplants. In 2016, the program was officially named the “Beijing Program” for leukemia treatment by the World Bone Marrow Transplant Association, and it is recommended as a reliable transplant solution for the global lack of all-in-one donors. The program has also been written into the international authoritative textbook for bone marrow transplantation and has been cited by the relevant guidelines of the Bone Marrow Transplant Association of the United States and the United Kingdom.
"20% of leukemia patients in Japan cannot find a fully compatible donor. After treatment with the Chinese regimen, the effect is good after the treatment." Xia Yang, vice president of the World Cell Therapy Organization, said that China's original solution for leukemia treatment is the world. The impact is far-reaching. The former president of the European Society of Hematology, Faby, said that the Chinese program has set new standards for leukemia bone marrow transplantation technology, and tens of millions of leukemia patients worldwide have benefited. "At present, the proportion of patients in Europe and the United States who use Chinese treatment programs has increased significantly. "[Source: Xinhua News Agency]